caa a22 4500 475742826 CHVBK 20180406123504.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1007/s002400000116 doi (NATIONALLICENCE)springer-10.1007/s002400000116 Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer [Elektronische Daten] [T. Liukkonen, P. Lipponen, M. Raitanen, E. Kaasinen, M. Ala-Opas, P. Rajala, V.-M. Kosma] Immunoreactivity of p21WAF1/CIP1 and cyclin D1 proteins was assessed in a cohort of 207 patients with superficial (pTa-pT1) bladder cancer followed up for a mean of 4.9 years. The results of the immunostainings were compared with T category, WHO grade, tumor cell proliferation rate (MIB-1 score), the expressions of p53 and bcl-2 as well as survival. Sixty-eight percent and 75% of the tumors were p21WAF1/CIP1 positive (≥5% of cells positive) and cyclin D1 positive (≥10% of cells positive), respectively. The p21WAF1/CIP1 expression was related to cyclin D1 immunolabelling (P < 0.001) but not to the other variables studied. The expression of cyclin D1 was inversely associated with T category (P=0.001), WHO grade (P=0.006), MIB-1 score (P=0.014), p53 expression (P=0.001), and bcl-2 (P=0.011) immunoreactivity. In univariate analysis, T category (P=0.0001), WHO grade (P < 0.0001), MIB-1 score (P < 0.0001), bcl-2 (P=0.0092), p53 (P=0.0016) and p21WAF1/CIP1 (P=0.009) expressions were significant prognostic factors with regard to tumor progression, whereas cyclin D1 was without any prognostic significance (P=0.1). Out of 123 p21 positive tumors 21 progressed, whereas only 2 out of 58 p21 negative tumors progressed. In multivariate analysis, the MIB-1 score was the only independent predictor of cancer-specific survival (P=0.03), whereas tumor grade (P=0.002) and cyclin D1 expression (P=0.04) were independent predictors of tumor recurrence. Only the WHO grade (P=0.04) retained its prognostic value indicating the risk of progression. We suggest that in superficial bladder cancer p21WAF1/CIP1 and cyclin D1 immunohistochemistry provide no additional prognostic information compared with already established prognostic factors for predicting the risk of progressive disease. Springer-Verlag Berlin Heidelberg, 2000 Key words Superficial bladder cancer nationallicence p21WAF1/CIP1 nationallicence Prognosis nationallicence Cyclin D1 nationallicence Liukkonen T. Department of Surgery, Mikkeli Central Hospital, Porrassalmenkatu 35-37, Fin-50100 Mikkeli, Finland Tel.: +358 (0)15 3511; Fax: +358 (0)15 3512200, FI aut Lipponen P. Department of Pathology and Forensic Medicine, University of Kuopio, Finland, FI aut Raitanen M. Department of Surgery, Tampere University Hospital, Finland, FI aut Kaasinen E. Department of Surgery, Hyvinkää District Hospital, Finland, FI aut Ala-Opas M. Department of Urology, Kuopio University Hospital, Finland, FI aut Rajala P. Department of Surgery, Turku University Hospital, Finland, FI aut Kosma V.-M Department of Pathology and Forensic Medicine, Kuopio University Hospital, Finland, FI aut https://doi.org/10.1007/s002400000116 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002400000116 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liukkonen T. Department of Surgery, Mikkeli Central Hospital, Porrassalmenkatu 35-37, Fin-50100 Mikkeli, Finland Tel.: +358 (0)15 3511; Fax: +358 (0)15 3512200, FI aut NATIONALLICENCE 700 1- Lipponen P. Department of Pathology and Forensic Medicine, University of Kuopio, Finland, FI aut NATIONALLICENCE 700 1- Raitanen M. Department of Surgery, Tampere University Hospital, Finland, FI aut NATIONALLICENCE 700 1- Kaasinen E. Department of Surgery, Hyvinkää District Hospital, Finland, FI aut NATIONALLICENCE 700 1- Ala-Opas M. Department of Urology, Kuopio University Hospital, Finland, FI aut NATIONALLICENCE 700 1- Rajala P. Department of Surgery, Turku University Hospital, Finland, FI aut NATIONALLICENCE 700 1- Kosma V.-M Department of Pathology and Forensic Medicine, Kuopio University Hospital, Finland, FI aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer